Clinical Trial Detail

NCT ID NCT01593254
Title Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib (DASCERN)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Bristol-Myers Squibb
Indications

chronic myeloid leukemia

Therapies

Imatinib

Dasatinib

Age Groups: adult senior

Additional content available in CKB BOOST